Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Other Operating Expenses (2022 - 2024)

Historic Other Operating Expenses for Taysha Gene Therapies (TSHA) over the last 3 years, with Q3 2024 value amounting to $4.8 million.

  • Taysha Gene Therapies' Other Operating Expenses rose 68538.96% to $4.8 million in Q3 2024 from the same period last year, while for Jun 2025 it was $4.8 million, marking a year-over-year increase of 35427.23%. This contributed to the annual value of $4.8 million for FY2024, which is 35427.23% up from last year.
  • As of Q3 2024, Taysha Gene Therapies' Other Operating Expenses stood at $4.8 million, which was up 68538.96% from $449000.0 recorded in Q4 2023.
  • Taysha Gene Therapies' Other Operating Expenses' 5-year high stood at $36.4 million during Q4 2022, with a 5-year trough of $449000.0 in Q4 2023.
  • Its 3-year average for Other Operating Expenses is $10.6 million, with a median of $2.7 million in 2023.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first plummeted by 9876.72% in 2023, then soared by 68538.96% in 2024.
  • Taysha Gene Therapies' Other Operating Expenses (Quarter) stood at $36.4 million in 2022, then crashed by 98.77% to $449000.0 in 2023, then skyrocketed by 977.51% to $4.8 million in 2024.
  • Its last three reported values are $4.8 million in Q3 2024, $449000.0 for Q4 2023, and $616000.0 during Q3 2023.